Study Utilizing Puregraft Technology Shows Fat Transfer Can Be Used To Naturally Improve Breast Size & Shape

The authors transferred an average of 280 cc of Puregraft processed fat per procedure and measured the percent of fat remaining 1-year after injection using 3-dimensional imaging software. Dr. Sforza and colleagues reported that an average of 72% of implanted fat remained 1-year post-operatively and patients reported a satisfaction rate of "excellent" in 83% of cases. The authors concluded that fat transplanted to the breast utilizing Puregraft technology was both predictable and reproducible.

According to Dr. Sforza, "Our work demonstrates that new technology can now make larger breasts using your own fat in a predictable and efficient way." Added Dr. Sforza, "fat transfer in breast enlargement surgery is the future and how you treat the fat, in my mind, plays a role in achieving excellent results for patients." Added Bradford Conlan, Chief Executive Officer of Puregraft, "We believe this data reinforces what we already know–Puregraft offers both patients and physicians a reliable method for fat transfer."

The Puregraft family of products serve the needs of physicians performing fat transfer.  Within 15 minutes, a physician can have access to a patient's own purified, high quality fat tissue for aesthetic body contouring. Fat transfer remains one of the hottest growth segments in plastic and reconstructive surgery marketplace. Today, the Puregraft family of products have been used over 50,000 times in operating rooms around the world.

Learn more about Puregraft at www.thefatexperts.com

About Puregraft

Puregraft LLC is a private company owned by Bimini Technologies.  The Bimini portfolio of products also includes Kerastem Technologies LLC (www.kerastem.com) a leading hair growth company currently engaged in a Phase II clinical trial in the United States.  The Kerastem Hair Therapy is CE Mark approved outside the United States.  

Cautionary Statement Regarding Forward-Looking Statements

This press release may include "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as "will," "near future," "positioned," "provide," or other words or phrases of similar import that are intended to identify forward-looking statements. Similarly, statements herein that describe Puregraft LLC's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements, including: the clinical and commercial potential and success of the company's Puregraft product line; general economic and business conditions; and other risks and important factors that could cause actual results to differ materially from the forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this announcement, and Puregraft LLC undertakes no obligation to update the forward-looking statements to reflect subsequent events or circumstances after the date on which they were made.

¹ A Preliminary Assessment of the Predictability of Fat Grafting to Correct Silicone Breast Implant-Related Complications, Marcos Sforza MD, Katarina Andjelkov MD, PhD, Renato Zaccheddu MD, Rodwan Husein, Connor Atkinson. Aesthetic Surgery Journal published online 7 May 2016

Video - https://youtu.be/7GAxCpuFKpk

Logo - http://photos.prnewswire.com/prnh/20150916/267241LOGO

SOURCE Puregraft LLC

Related Links

http://www.thefatexperts.com